BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Thursday reported a loss of $64.7 million in its fourth quarter.

The Bedford, Massachusetts-based company said it had a loss of 29 cents per share.

The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share.

The biotechnology company posted revenue of $13.3 million in the period, missing Street forecasts. Four analysts surveyed by Zacks expected $15.1 million.

For the year, the company reported a loss of $265.9 million, or $1.42 per share. Revenue was reported as $52 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OCUL at https://www.zacks.com/ap/OCUL